Objective: To compare the efficacy, tolerability, and safety of once-daily therapy with amlodipine 5 mg/benazepril 10 mg vs amlodipine 5 mg, benazepril 10 mg, and placebo. Design: Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. Setting: Twenty-two clinical centres, including private practice groups and academic research clinics. Patients: A total of 530 patients between 21 and 80 years of age with essential hypertension were screened for the study, and 454 were randomised to treatment with amlodipine 5 mg/benazepril 10 mg, amlodipine 5 mg, benazepril 10 mg, or placebo for 8 weeks. Results: Amlodipine 5 mg/benazepril 10 mg produced greater reductions from baseline in sitting diastolic blood pressure than amlodipine 5 mg (P Ͻ 0.03), ben-
Introduction
Several studies have demonstrated that coadministration of a calcium antagonist and an ACE inhibitor produces an enhanced therapeutic effect and reduces dose-dependent side effects such as the oedema associated with the calcium antagonist. [1] [2] [3] [4] The efficacy, tolerability, and safety of combination therapy was evaluated in this randomised, double-blind, placebo-controlled, parallel-group, multicentre trial comparing the combination of amlodipine 5 mg/benazepril 10 mg with amlodipine 5 mg, benazepril 10 mg, and placebo in patients with essential hypertension. azepril 10 mg (P Ͻ 0.001), and placebo (P Ͻ 0.001). The response rate in the amlodipine 5-mg/benazepril 10-mg treatment group (66.4%) was better than that observed in the amlodipine 5-mg (50.0% P Ͻ 0.02), benazepril 10-mg (38.3% P Ͻ 0.001), and placebo (24.4% P Ͻ 0.001) groups. There was no significant difference in heart rate among the four groups. The incidence of oedema in the amlodipine 5-mg/benazepril 10-mg (1.7%) group was somewhat less than that in the amlodipine 5-mg (4.5%) group. Conclusions: Therapy with amlodipine 5 mg/benazepril 10 mg was well tolerated and was superior to amlodipine 5 mg, benazepril 10 mg, and placebo in reducing sitting diastolic blood pressure in patients with essential hypertension.
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Subjects and methods
Outpatients between 21 and 80 years of age with uncomplicated essential primary hypertension were eligible to participate in the study. Specifically required was a mean sitting diastolic blood pressure (MSDBP) у100 mm Hg and р115 mm Hg at the screening and randomisation (ie, baseline) visits, with a variation of no more than 10 mm Hg in the MSDBP.
Written informed consent was obtained from each patient. After withdrawal of previous antihypertensive medication over a 2-week washout period, patients were entered into a single-blind, placebo run-in period which lasted 2 to 4 weeks. At the end of the placebo run-in period, patients who met the inclusion criteria were randomised according to a computer-generated code to double-blind treatment with amlodipine 5 mg/benazepril 10 mg
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(administered as separate components), amlodipine 5 mg, benazepril 10 mg, or placebo. Patients received double-blind treatment for 8 weeks. Study medication was to be taken every day at approximately 8.00 am except on the morning of study visits. On visit days, patients arrived at the investigator's office between 7.00 am and 10.00 am, so that visit procedures were completed approximately 24 h post-dosing.
To conceal treatment identity, the study drugs were packaged by using a double-dummy technique. Each patient received two bottles of study medication during the double-blind period; one bottle contained amlodipine 5 mg or matching placebo and the other bottle contained benazepril 10 mg or matching placebo.
Patients were evaluated at a screening visit, at the start of double-blind treatment (baseline), and after 4 and 8 weeks of double-blind treatment. Blood pressure was measured according to the World Health Organization criteria, 5 by the same person. All sitting blood pressure measurements were made three times: after the patient had been seated for 5 min and thereafter at 1-to 2-min intervals. At each visit, the patient's pulse rate was measured for 30 seconds in the sitting position.
Adverse events were documented at each visit by questioning and examining the patient. The investigator judged the relationship of each adverse event to the trial drug as not related, remotely, possibly, probably, or definitely related.
Statistical evaluation
The planned sample size was 111 acceptable patients (ie, patients who met the double-blind entry criteria and completed all visits) per treatment group. The sample size was calculated to provide 80% power to detect a 3 mm Hg difference in MSDBP between two treatment groups at a 0.05 level of statistical significance (two-tailed), assuming a standard deviation of 8 mm Hg for each treatment group.
Comparability of the four treatment groups at baseline with respect to demographic and medical history data was evaluated by using a chi-square test or F-test. An F-test was also used to determine comparability at baseline with respect to mean sitting diastolic and systolic blood pressures; sitting pulse rate; and body weight.
With respect to each efficacy variable (change from baseline in MSDBP and mean sitting systolic blood pressure, MSSBP), an intent-to-treat analysis was performed based on data from all randomised patients who had a baseline measurement and at least one post-baseline measurement. Analyses of efficacy variables were carried out at end point (ie, the last post-baseline measurement for each patient).
Between-treatment group differences were calculated based on least squares means from the twoway analysis of covariance model with treatment group and trial centre as factors and baseline value as the covariate. The response rate, ie, the proportion of patients achieving a successful response to treatment (defined as MSDBP Ͻ90 mm Hg or a у10 mm Hg decrease from baseline to end point in MSDBP) in each treatment group was compared by using a one-way logistic model with treatment group as a factor.
Results
Patients
Of the 530 patients enrolled in the placebo run-in period, 454 were randomised to double-blind treatment. A total of 400 patients completed the trial and 54 discontinued prematurely: 21 owing to unsatisfactory therapeutic response, 17 owing to adverse events (regardless of relationship to trial drug), and 16 owing to other reasons. A total of 450 patients were included in the efficacy analysis, and 451 patients were included in the safety analysis.
The patient population was predominantly white (84%) and male (63%), with a mean age of 53.8 years. The treatment groups were comparable with respect to all demographic characteristics.
Blood pressure
The change from baseline to end point in MSDBP was significantly greater for the three active treatment groups compared with placebo (P Ͻ 0.001; Table 1 ). Amlodipine 5 mg/benazepril 10 mg produced greater decreases from baseline in MSDBP than amlodipine 5 mg (P = 0.029) and benazepril 10 mg (P Ͻ 0.001).
The change from baseline to end point in MSSBP was significantly greater for the three active treatment groups compared with placebo (P р 0.001; Table 1 ). The amlodipine 5-mg/benazepril 10-mg group had decreases from baseline in MSSBP that were similar to those in the amlodipine 5-mg group, but significantly greater than those in the benazepril 10-mg group (P Ͻ 0.002).
Successful response to treatment (a MSDBP Ͻ90 mm Hg or a decrease of 10 mm Hg or more from baseline) at end point was achieved in 66.4% of patients in the amlodipine 5-mg/benazepril 10-mg group, 50.0% in the amlodipine 5-mg group, 38.3% in the benazepril 10-mg group, and 24.4% in the placebo group. Comparison of these response rates demonstrated that combination therapy with amlodipine 5 mg/benazepril 10 mg was superior to treatment with amlodipine 5 mg, benazepril 10 mg, and placebo (P = 0.014, P Ͻ 0.001, and P Ͻ 0.001, respectively; Figure 1 ). Amlodipine 5 mg alone and benazepril 10 mg alone produced higher response rates than placebo (P Ͻ 0.001 and P = 0.024, respectively). No significant difference in heart rate among the four groups was observed (Table 1) . 
Between treatment group comparisons of MSSBP
Adverse events
The incidence of adverse events in the amlodipine 5-mg/benazepril 10-mg group (37.3%) was slightly lower than that in the amlodipine 5-mg group (46.4%) and the placebo group (46.1% NS). Adverse events occurred in 34.5% of patients in the benazepril 10-mg group (Table 2) . No patients in the amlodipine 5-mg/benazepril 10-mg group reported peripheral oedema; five (4.5%) did so in the amlodipine 5-mg group, two (1.7%) in the benazepril 10-mg group, and one (0.9%) in the placebo group. Headache was more common in patients on placebo than in patients on any other treatment. Seventeen patients discontinued prematurely because of an adverse event (regardless of relationship to the trial drug): four patients treated with amlodipine 5 mg/benazepril 10 mg, four treated with amlodipine 5 mg, two treated with benazepril Journal of Human Hypertension 10 mg and seven treated with placebo. Ten of these 17 patients-five in the amlodipine 5-mg/benazepril 10-mg group, three in the amlodipine 5-mg group, and two in the placebo group-discontinued prematurely due to a drug-related adverse event.
Eight patients had one or more adverse events that were considered serious (regardless of relationship to the trial drug): one patient in the amlodipine 5-mg/benazepril 10-mg group (angioedema); three patients in the amlodipine 5-mg group (one with sinusitis, one with a seizure, and one with unstable angina and a myocardial infarction); two patients in the benazepril 10-mg group (one with kidney stones and one with bone spur surgery) and two patients in the placebo group (one with urinary tract infection, congestive heart failure, and prostate cancer, and the other with prostate cancer).
Discussion
In our large-scale, multicentre, placebo-controlled study, therapy with a calcium antagonist amlodipine (5 mg)/benazepril (10 mg) combination was superior to treatment with either of these agents alone in lowering MSDBP. Further, a higher response rate was achieved with amlodipine 5 mg/benazepril 10 mg than with amlodipine 5 mg or benazepril 10 mg alone.
Treatment with amlodipine 5 mg/benazepril 10 mg was well tolerated. Headache, the most frequently reported adverse event in all treatment groups, occurred more often in patients treated with placebo than in patients in any other treatment group.
In this study, the incidence of oedema (regardless of trial-drug relationship) in the amlodipine 5-mg/benazepril 10-mg group was somewhat less than that in the amlodipine 5-mg group corroborating earlier studies. [1] [2] [3] [4] The vasodilatory oedema occurring with dihydropyridine calcium antagonist is the result of arteriolar dilatation which increases transcapillary pressure. It is in general unresponsive to diuretic therapy since diuretics have little effect on transcapillary pressure. In contrast, ACE inhibitors will open up postcapillary vessels, thereby normalising transcapillary pressure and reducing vasodilatory oedema.
Combination therapy for hypertension may be useful in those patients who do not achieve satisfactory blood pressure control with any dihydropyridine calcium antagonist or any ACE inhibitor or who have dose dependent side effects during treatment with amlodipine. The results of our study demonstrate that the amlodipine 5-mg/benazepril 10-mg regimen provides an effective alternative in such patients. However, that blood pressure reduction is not synonymous with reduction in target organ damage or morbidity and mortality. The present short-term study allows no conclusion in this regard.
We conclude that in this large scale study, more effective blood pressure control was achieved with once-daily combination therapy of amlodipine 5 mg/benazepril 10 mg in patients with essential hypertension than with monotherapy and that combination therapy was well tolerated.
